Search Results

You are looking at 101 - 110 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary

Arantzazu Barquín García, Sara Palacios-Zambrano, Felipe Lozano Alarcón, Beatriz Paumard-Hernández, Miguel Quiralte Pulido, Paloma Navarro, Laura Rodríguez, Isabel Salas Villar, and Jesús García-Donas

megabase in 2008 cost approximately $8,000, but by 2013, it cost $0.10. 2 , 3 Carcinoma of unknown primary (CUP) is one of the greatest challenges for clinicians. 4 Almost all tumors of this type (90%) are initially categorized as adenocarcinomas based

Full access

Optimal Treatment of Unresectable Nonmelanoma Skin Cancers

Thomas Olencki

with cutaneous squamous cell carcinoma (SCC), metastatic basal cell carcinoma (BCC), and metastatic Merkel cell carcinoma (MCC). Dr. Olencki noted the few options available for these rare cancers and a lack of clinical trials for guidance, and shared

Full access

Comparison of Pathologic Stage in Patients Receiving Esophagectomy With and Without Preoperative Chemoradiation Therapy for Esophageal SCC

Bing-Yen Wang, Ping-Yi Lin, Shiao-Chi Wu, Hui-Shan Chen, Po-Kuei Hsu, Chih-Shiun Shih, Chao-Yu Liu, Chia-Chuan Liu, and Yao-Li Chen

Background Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies worldwide. Most patients die within 1 year of diagnosis, and the 5-year overall survival (OS) rate is less than 20%. 1 , 2 According to the NCCN

Full access

NCCN Guidelines Updates: Management of Metastatic Kidney Cancer

Eric Jonasch

replace current options in the upfront metastatic setting for clear cell renal cell carcinoma (ccRCC), based on recently reported pivotal trials. Some of these new regimens are not yet incorporated into the NCCN Guidelines, but are expected to be soon

Full access

Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

Biphenotypic (hepatobiliary) primary liver carcinomas [B(H-B)PLCs] are rare tumors representing a heterogenous group of primary liver malignancies with evidence of both biliary and hepatocellular differentiation. These tumors have been referred to

Full access

Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam‐Trastuzumab Deruxtecan

Navika D. Shukla, Ryan S. Chiang, and Alexander D. Colevas

other cancer settings. This includes salivary duct carcinomas (SDCs), which have been commonly linked to the overexpression or amplification of HER2 in gene profiling studies. 1 – 7 More recently, newer second- and third-generation anti-HER2 agents

Full access

Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

inhibitors to block BER in tumors with HRD results in the accumulation of double-strand breaks and ultimately cell death, the so-called therapeutic synthetic lethality. This report presents a case of recurrent endometrial carcinoma occurring in a patient

Full access

Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma

Jonathan S. Zager, Jane L. Messina, L. Frank Glass, and Vernon K. Sondak

/print certificate. Release date: March 10, 2014; Expiration date: March 10, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Identify areas of uncertainty surrounding management of Merkel cell carcinoma

Full access

Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson

Historically, renal cell carcinoma (RCC) has been a formidable cancer with limited responses to both radiation and systemic management. Currently, surgery offers the only real chance of cure for patients with cancer localized to the kidney and

Full access

Counterpoint: Sentinel Lymph Node Biopsy Is Not Indicated for Ductal Carcinoma In Situ

Stephen B. Edge and David G. Sheldon

ductal carcinoma in situ patients . Ann Surg Oncol 2000 ; 7 : 15 – 20 . 2 Cox CE Nguyen K Gray RJ . Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001 ; 67 : 513 – 519 . 3 Klauber